These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15009836)

  • 1. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation.
    Pescovitz MD
    Pediatr Transplant; 2004 Feb; 8(1):9-21. PubMed ID: 15009836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in immunotherapy rituximab.
    El-Habbash MM; Alwindi AM
    Saudi Med J; 2007 Nov; 28(11):1635-44. PubMed ID: 17965780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of rituximab in organ transplantation.
    Becker YT; Samaniego-Picota M; Sollinger HW
    Transpl Int; 2006 Aug; 19(8):621-8. PubMed ID: 16827678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab.
    Keren A; Hayes HM; O'Driscoll G
    Transplant Proc; 2006 Jun; 38(5):1520-2. PubMed ID: 16797348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTLD treatment: reducing the chemotherapy burden through addition of rituximab.
    Dharnidharka VR; Gupta S
    Pediatr Transplant; 2010 Feb; 14(1):10-1. PubMed ID: 20078838
    [No Abstract]   [Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
    Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
    Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
    Pescovitz MD
    Am J Transplant; 2006 May; 6(5 Pt 1):859-66. PubMed ID: 16611321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel uses of rituximab].
    Frenzel L
    Rev Prat; 2013 Dec; 63(10):1349-53. PubMed ID: 24579323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
    González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
    Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
    Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
    Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
    Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
    Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
    Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant lymphoproliferative disease in children following solid organ transplant and rituximab--the final answer?
    Gross TG
    Pediatr Transplant; 2007 Sep; 11(6):575-7. PubMed ID: 17663676
    [No Abstract]   [Full Text] [Related]  

  • 16. B cell monitoring of transplant patients treated with anti-CD20.
    Abdallah KO; Prak ET
    Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.
    Trahair TN; Wainstein B; Manton N; Bourne AJ; Ziegler JB; Rice M; Russell SJ
    Pediatr Blood Cancer; 2008 Feb; 50(2):366-9. PubMed ID: 16732583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
    Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME
    Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug insight: rituximab in renal disease and transplantation.
    Salama AD; Pusey CD
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):221-30. PubMed ID: 16932428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review.
    Kaczmarek I; Deutsch MA; Sadoni S; Brenner P; Schmauss D; Daebritz SH; Weiss M; Meiser BM; Reichart B
    J Heart Lung Transplant; 2007 May; 26(5):511-5. PubMed ID: 17449422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.